Pharmacotherapy and pulmonary fibrosis risk after SARS-CoV-2 infection-response to Guangting Zeng and Yuchi Zhou

Lancet Reg Health Am. 2023 Oct 5:26:100611. doi: 10.1016/j.lana.2023.100611. eCollection 2023 Oct.

Ayodeji Adegunsoye^{1

2}, Rachel Baccile³, Thomas J Best³, Victoria Zaksas^{4

5}, Hui Zhang³, Rasika Karnik⁶, Bhakti K Patel¹, Anthony E Solomonides^{7

8}, William F Parker¹, Julian Solway^{1

8}

¹ Section of Pulmonary & Critical Care, Department of Medicine, The University of Chicago, Chicago, IL, USA.
² Committee on Clinical Pharmacology & Pharmacogenomics, The University of Chicago, Chicago, IL, USA.
³ Center for Health and the Social Sciences, The University of Chicago, Chicago, IL, USA.
⁴ Center for Translational Data Science, The University of Chicago, Chicago, IL, USA.
⁵ Clever Research Lab, Springfield, IL, USA.
⁶ Section of General Internal Medicine, Department of Medicine, The University of Chicago, Chicago, IL, USA.
⁷ Outcomes Research Network, Research Institute, NorthShore University HealthSystem, Evanston, IL, USA.
⁸ The Institute for Translational Medicine, University of Chicago, Chicago, IL, USA.

No abstract available

Grants and funding